Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of DJI136 (DLL3-targeted CAR-T) in Extensive-Stage Small Cell Lung Cancer
2025-523276-23-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of DJI136 in small cell lung cancer (SCLC), sponsored by Novartis. Primary endpoints: Safety and tolerability (AEs, SAEs, lab values, vital signs, ECGs, DLTs) and Overall response rate (RECIST v1.1) in Phase II Group A. Planned start May 2026; status: authorised.
02
Drugs
DJI136
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-523276-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523276-23-00.